Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
There are few papers on the combination therapy of deferiprone (DFP) and deferasirox (DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A total of 6 patients with β-TM (5 males and 1 female) with a mean age of 23.8±5.8 years (ranging from 17 to 31) used this tre...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-01-01
|
| Series: | Clinics and Practice |
| Subjects: | |
| Online Access: | https://www.clinicsandpractice.org/index.php/cp/article/view/912 |
| _version_ | 1828358462200872960 |
|---|---|
| author | Hossein Karami Mehrnoush Kosaryan Arash Hadian Amree Hadi Darvishi-Khezri Masoomeh Mousavi |
| author_facet | Hossein Karami Mehrnoush Kosaryan Arash Hadian Amree Hadi Darvishi-Khezri Masoomeh Mousavi |
| author_sort | Hossein Karami |
| collection | DOAJ |
| description | There are few papers on the combination therapy of deferiprone (DFP) and deferasirox (DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A total of 6 patients with β-TM (5 males and 1 female) with a mean age of 23.8±5.8 years (ranging from 17 to 31) used this treatment regimen. The mean doses of DFP and DFX were 53.9±22.2 and 29.3±6.8 mg/kg/day, respectively. The duration of treatment was 11.5±4.6 months. Their serum ferritin levels were measured to be 2800±1900 and 3400±1600 ng/mL before and after treatment, respectively (p<0.6). Their cardiac magnetic resonance imaging (MRI) T2* values were 16.69±15.35 vs 17.38±5.74 millisecond (ms) before and after treatment, respectively (p < 0.9). Although there was no significant difference between their cardiac MRI T2* values before and after treatment statistically, the values improved after combination therapy with DFP and DFX in most of the patients. Liver MRI T2 * values were changed from 2.12±0.98 to 3.03±1.51 ms after treatment (p < 0.01); Further, their liver T2* values and liver iron concentration (LIC) were improved after treatment. Our study found that cardiac MRI T2* values, liver MRI T2* values, and LIC were improved after combination therapy with DFP and DFX in β-TM patients and that DFP and DFX combination therapy could be used to alleviate cardiac and liver iron loading. |
| first_indexed | 2024-04-14T03:30:12Z |
| format | Article |
| id | doaj.art-7ba13c10b1ad4ed7b54729f034957402 |
| institution | Directory Open Access Journal |
| issn | 2039-7275 2039-7283 |
| language | English |
| last_indexed | 2024-04-14T03:30:12Z |
| publishDate | 2017-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Clinics and Practice |
| spelling | doaj.art-7ba13c10b1ad4ed7b54729f0349574022022-12-22T02:15:00ZengMDPI AGClinics and Practice2039-72752039-72832017-01-017110.4081/cp.2017.912372Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia majorHossein Karami0Mehrnoush Kosaryan1Arash Hadian Amree2Hadi Darvishi-Khezri3Masoomeh Mousavi4Department of Pediatrics, Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, SariDepartment of Pediatrics, Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, SariStudent Research Committee, Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, SariStudent Research Committee, Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, SariDepartment of Anesthesiology, Babol University of Medical Sciences, BabolThere are few papers on the combination therapy of deferiprone (DFP) and deferasirox (DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A total of 6 patients with β-TM (5 males and 1 female) with a mean age of 23.8±5.8 years (ranging from 17 to 31) used this treatment regimen. The mean doses of DFP and DFX were 53.9±22.2 and 29.3±6.8 mg/kg/day, respectively. The duration of treatment was 11.5±4.6 months. Their serum ferritin levels were measured to be 2800±1900 and 3400±1600 ng/mL before and after treatment, respectively (p<0.6). Their cardiac magnetic resonance imaging (MRI) T2* values were 16.69±15.35 vs 17.38±5.74 millisecond (ms) before and after treatment, respectively (p < 0.9). Although there was no significant difference between their cardiac MRI T2* values before and after treatment statistically, the values improved after combination therapy with DFP and DFX in most of the patients. Liver MRI T2 * values were changed from 2.12±0.98 to 3.03±1.51 ms after treatment (p < 0.01); Further, their liver T2* values and liver iron concentration (LIC) were improved after treatment. Our study found that cardiac MRI T2* values, liver MRI T2* values, and LIC were improved after combination therapy with DFP and DFX in β-TM patients and that DFP and DFX combination therapy could be used to alleviate cardiac and liver iron loading.https://www.clinicsandpractice.org/index.php/cp/article/view/912Deferipronedeferasiroxiron overload?-thalassemia majorMRI T2*. |
| spellingShingle | Hossein Karami Mehrnoush Kosaryan Arash Hadian Amree Hadi Darvishi-Khezri Masoomeh Mousavi Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major Clinics and Practice Deferiprone deferasirox iron overload ?-thalassemia major MRI T2*. |
| title | Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major |
| title_full | Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major |
| title_fullStr | Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major |
| title_full_unstemmed | Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major |
| title_short | Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major |
| title_sort | combination iron chelation therapy with deferiprone and deferasirox in iron overloaded patients with transfusiondependent β thalassemia major |
| topic | Deferiprone deferasirox iron overload ?-thalassemia major MRI T2*. |
| url | https://www.clinicsandpractice.org/index.php/cp/article/view/912 |
| work_keys_str_mv | AT hosseinkarami combinationironchelationtherapywithdeferiproneanddeferasiroxinironoverloadedpatientswithtransfusiondependentbthalassemiamajor AT mehrnoushkosaryan combinationironchelationtherapywithdeferiproneanddeferasiroxinironoverloadedpatientswithtransfusiondependentbthalassemiamajor AT arashhadianamree combinationironchelationtherapywithdeferiproneanddeferasiroxinironoverloadedpatientswithtransfusiondependentbthalassemiamajor AT hadidarvishikhezri combinationironchelationtherapywithdeferiproneanddeferasiroxinironoverloadedpatientswithtransfusiondependentbthalassemiamajor AT masoomehmousavi combinationironchelationtherapywithdeferiproneanddeferasiroxinironoverloadedpatientswithtransfusiondependentbthalassemiamajor |